PHASE 1, SINGLE-CENTER, DOSE-ESCALATING, OPEN-LABEL, SAFETY CLINICAL TRIAL OF PARENTERAL ASCORBATE-MEGLUMINE AS A NOVEL MAGNETIC RESONANCE IMAGING-GUIDED ADJUNCTIVE THERAPEUTIC FOR STEREOTACTIC RADIOSURGERY